Submissions from 2017
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13ra2, EPHA2, and survivin, in adults with second-line recurrent GBM, D A. Reardon, B Nabors, P Kumthekar, M Badruddoja, K Fink, F Lieberman, J Hu, E Dunbar, Tobias Walbert, D Schiff, J Sherman, D Tran, L S. Ashby, N Butowski, F Iwamoto, C Moertel, M Schulder, J Chen, J Bullington, S Shemesh, C Brooks, T Goswami, and D M. Peereboom
Depletion of 5-hydroxymethylcytosine in aggressive G-CIMP subtype, Thais S. Sabedot, Laila M. Poisson, Ana de Carvalho, and Houtan Noushmehr
Predictive signature of malignant recurrence in G-CIMP tumors, C F. Souza and Houtan Noushmehr
Quantifiable levels of the transgene, cytosine deaminase, in tumor samples following intravenous delivery of toca 511 in patients with recurrent high grade glioma, Tobias Walbert, D Bota, M Vogelbaum, Steven N. Kalkanis, L Liau, Tom Mikkelsen, H Gruber, J S. Shorr, M Rodriguez-Aguirre, Derek Ostertag, L Mitchell, D Jolly, and Timothy Cloughesy
Intravenous delivery of toca 511 in patients with high grade glioma results in quantifiable expression of cytosine deaminase in tumor tissue, Tobias Walbert, D Bota, M Vogelbaum, Steven N. Kalkanis, L Liau, Tom Mikkelsen, H Gruber, J S. Shorr, M Rodriguez-Aquirre, Derek Ostertag, L Mitchell, D Jolly, and Timothy Cloughesy
Deciphering glioma intrinsic transcriptional subtypes identifies tumor evolution associates with changes in immune-microenvironment, Q H. Wang, B L. Hu, X Hu, M Squatrito, Lisa Scarpace, Ana C. de Carvalho, S Lyu, P P. Li, Y Li, F P. Barthel, HJ Cho, Y H. Lin, N Satani, E Martinez-Ledesma, S Y. Zheng, E Chang, A Olar, Z D. Lan, G Finocchiaro, J J. Phillips, M S. Berger, K Gabrusiewicz, G C. Wang, E Eskilsson, J Hu, Tom Mikkelsen, R Depinho, F Muller, A Heimberger, E Sullman, D H. Nam, and R Verhaak
